CGC
Canopy Growth Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$0.97
−0.02%Year over year
Reported trailing growth
- Revenue
- +16.9%
- EBITDA
- +54.1%
- EBIT
- +7.3%
- EPS
- +83.8%
- Free cash flow
- +37.1%
- Operating cash flow
- +36.9%
Forward estimates
Based on analyst estimates
- Revenue
- -21.2%
- EBITDA
- +123.0%
- EPS
- +86.2%
Three-year CAGR
- Revenue
- -5.1%
- EBITDA
- +60.7%
- EBIT
- +37.6%
- Net income
- +56.0%
- EPS
- +84.1%
- Free cash flow
- +60.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026